Favorable results of patients with pT1a, b, c, lymph node-negative early breast cancer in the long interval

J Cancer Res Ther. 2019 Jul-Sep;15(5):1051-1056. doi: 10.4103/jcrt.JCRT_1275_16.

Abstract

Background: The clinical characteristics of patients who had lymph node-negative early breast cancer were assessed.

Patients and methods: We assessed a total of 576 patients in the study, including 74 patients (12.8%) with T1a, 119 patients (20.7%) T1b, and 367 patients (63.7%) with T1c. Patients with T1 tumors were further classified into three groups according to hormone receptor (HR) and human epidermal growth factor-receptor 2 (HER2) status.

Results: In patients with T1a, the disease-free survival (DFS) rate was 98.4% at 2 years (P = 0.001). In subgroup analysis of early breast cancers, 10-year-DFS rates of the patients in HR+/HER2-, HR-/HER2+, and HR-/HER2- subgroups were not significantly different (P = 0.917).

Conclusion: The T1a group had a worse prognosis than T1b and T1c groups in second years (P = 0.001); however, there was not statistically important difference between HR+, HER2+ and triple negative subgroups (P = 0.917). Although there are differences in patients and tumor features, the prognosis of patients with T1a, b, c N0M0 breast cancer is excellent.

Keywords: Early breast cancer; T1a; b; c; treatment.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology*
  • Disease-Free Survival
  • Female
  • Humans
  • Lymph Nodes / metabolism
  • Lymph Nodes / pathology*
  • Middle Aged
  • Neoplasm Staging / methods
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Receptor, ErbB-2